Global Press Release: Pfizer and Merck to generate $19.5 billion in global sales of new antiviral pills

Posted on Dec 16, 2021

Airfinity’s antiviral revenue forecast shows Pfizer will dominate the market with sales of $17 billion for its antiviral pill Paxlovid, while Merck’s Molnupiravir will generate $2.5 billion.

The US is expected to be the biggest buyer of these pills with revenue estimated to be $10.8 billion. The EU and UK are expected to spend $4.9 billion.

Airfinity predicts Pfizer’s Paxlovid treatment will have the majority market share due to sustained higher efficacy in its full results from the high-risk EPIC-HR trial. 

The forecast predicts sales of antiviral treatments based on the proportion of projected cases aimed to receive treatment, and the number of courses expected to be procured per case, by each country. The anticipated sales would  take up 56% of Pfizer’s available Paxlovid production in 2022 and 25% of Merk’s Molnupiravir 2022 production. 

Revenue generated from the rest of the world is estimated at $3.7bn. This excludes countries included in Medicines Patent Pool (MPP) agreements for Paxlovid and Molnupiravir. Airfinity predicts additional generic manufacturing under these agreements won't produce at scale until 2023. 

Airfinity’s Lead Analyst for Treatments Dr Arsalan Azad says, “Antiviral treatments are the new frontier in the fight against Covid-19. Antiviral pills will be easier to produce, distribute and face less hesitancy than vaccines. But 2022 looks set to see a supply and demand mismatch, countries who can buy directly from Pfizer and Merck should be able to secure enough supply to treat their high risk populations. However the 112 countries in the MPP agreement may not get access to these pills in any meaningful capacity until 2023.”


To download the full COVID-19 Treatments 2022 Revenue Forecast, click here.


The data and other information published herein are provided on an "as is basis". This report, and the data and analyses herein, was prepared for general circulation and should not be considered an investment recommendation or construed as investment advice. Airfinity Ltd does not warrant the accuracy, adequacy or completeness of the information and data contained herein and expressly disclaims liability for errors or omissions in this information and data. No warranty of any kind, implied, expressed or statutory, is given in conjunction with the information and data. Airfinity Ltd accepts no liability for any loss or damage arising out of the use or misuse of or reliance on the information provided including, without limitation, any loss of profits or any other damage, direct or consequential. Airfinity Ltd does and seeks to do business with companies covered in its analysis as well as other interested parties. Airfinity Ltd is not regulated by any financial authority.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022